NCT01791712

Brief Summary

Following the concept of "peak concentration hypothesis", which suggest the cutting peak of pro- and anti-inflammatory mediators would result in restoring a situation of immunohomeostasis. The investigators conducted the prospective randomized controlled trial aimed to compare the clearance efficacy between on-line hemodiafiltration and high-flux hemodialysis in sepsis-related acute kidney injury patients. The lowering cytokines level during sepsis is postulated to improved outcomes in sepsis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable sepsis

Timeline
Completed

Started Jan 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

October 11, 2011

Completed
1.4 years until next milestone

First Posted

Study publicly available on registry

February 15, 2013

Completed
Last Updated

February 15, 2013

Status Verified

February 1, 2013

Enrollment Period

1.7 years

First QC Date

October 11, 2011

Last Update Submit

February 12, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reduction in plasma Vascular Endothelial Growth Factor (VEGF)level

    At time 0-hour and 4-hour of the study dialysis session

Secondary Outcomes (3)

  • Intradialytic hypotension

    During 4 hours of the study dialysis session

  • Renal recovery (at 30 days)

    participants will be followed for the renal recovery (dialysis-free) for the 30 days from the first initiation of dialysis

  • Hospital patient mortality

    participants will be followed for the duration of hospital stay (an expected average of 5 weeks)

Study Arms (2)

On-line hemodiafiltration

EXPERIMENTAL

On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm

Procedure: On-line hemodiafiltration

High-flux hemodialysis (control)

ACTIVE COMPARATOR

The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.

Procedure: High-flux Hemodialysis

Interventions

pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min

Also known as: Nikkiso dialysis machine, ARROW dual lumen dialysis catheter, PureFlux -150H synthetic membrane dialyzer
On-line hemodiafiltration

blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min

High-flux hemodialysis (control)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Sepsis
  • acute kidney injury (RIFLE classification F)
  • Age more than 18

You may not qualify if:

  • Hemodynamic instability
  • Whom written informed consent could not be obtained

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Chulalongkorn Memorial Hospital

Bangkok, Bangkok, 10330, Thailand

Location

MeSH Terms

Conditions

SepsisAcute Kidney Injury

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Khajohn Tiranathanagul, M.D.

    Chulalongkorn University

    PRINCIPAL INVESTIGATOR
  • Wiwat Chancharoenthana, M.D.

    Chulalongkorn University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

October 11, 2011

First Posted

February 15, 2013

Study Start

January 1, 2010

Primary Completion

October 1, 2011

Study Completion

October 1, 2011

Last Updated

February 15, 2013

Record last verified: 2013-02

Locations